Budesonide Inhaler Market Report 2026

Budesonide Inhaler Market Overview

• Budesonide Inhaler market size has reached to $6.88 billion in 2025 • Expected to grow to $10.25 billion in 2030 at a compound annual growth rate (CAGR) of 8.3% • Growth Driver: Surge In Respiratory Disorders Fueling The Growth Of The Market Due To Increasing Air Pollution And Chronic Disease Prevalence • Market Trend: Rising Focus On Generic Budesonide Inhalers To Expand Access And Capitalize On Patent Expirations • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Budesonide Inhaler Market?

Budesonide inhaler is a respiratory device that delivers the corticosteroid medication budesonide directly into the lungs. It helps reduce inflammation in the airways, making it easier to breathe. Budesonide inhaler is prescribed for long-term management of respiratory diseases. The main types of products in the budesonide inhaler market are metered-dose inhalers (MDIs), dry powder inhalers (DPIs), nebulizers, and combination inhalers. Metered-dose inhalers (MDIs) refer to handheld medical devices used to deliver a specific amount of medication directly to the lungs in the form of a short burst of aerosolized medicine. The various dosage forms include aerosols, dry powder, suspension, and spray, indicated for different indications including asthma, chronic obstructive pulmonary disease, and allergic rhinitis. The different end users encompass hospitals, outpatient clinics, homecare settings, and pharmacies.

What Is The Budesonide Inhaler Market Growth Forecast?

The budesonide inhaler market size is expected to see strong growth in the next few years. It will grow to $10.25 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to chronic respiratory disease burden, smart inhaler development, outpatient respiratory care growth, preventive asthma management, emerging market demand. Major trends in the forecast period include rising demand for long-term respiratory control, increased adoption of combination inhalers, growth in homecare respiratory management, expansion of pediatric and geriatric usage, focus on improved inhaler delivery efficiency.

Global Budesonide Inhaler Market Segmentation

1) By Product Type: Metered-Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), Nebulizers, Combination Inhalers 2) By Dosage Form: Aerosols, Dry Powder, Suspension, Spray 3) By Indication: Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis 4) By End User: Hospitals, Outpatient Clinics, Homecare Settings, Pharmacies Subsegments: 1) By Metered-Dose Inhalers: Pressurized Metered-Dose Inhalers, Breath-Actuated Metered-Dose Inhalers, Spacer-Compatible Metered-Dose Inhalers, Hydrofluoroalkane Propellant-Based Metered-Dose Inhalers 2) By Dry Powder Inhalers: Single-Dose Dry Powder Inhalers, Multi-Dose Dry Powder Inhalers, Capsule-Based Dry Powder Inhalers, Reservoir-Based Dry Powder Inhalers 3) By Nebulizers: Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers, Homecare Nebulizers, Hospital-Use Nebulizers 4) By Combination Inhalers: Budesonide And Formoterol Inhalers, Budesonide And Salmeterol Inhalers, Budesonide, Glycopyrrolate, And Formoterol Inhalers, Budesonide And Vilanterol Inhalers

What Is The Driver Of The Budesonide Inhaler Market?

The rising prevalence of respiratory disorders is expected to propel the growth of the budesonide inhaler market going forward. Respiratory disorders are medical conditions that affect the lungs and airways, making breathing difficult and often causing symptoms such as coughing, wheezing, and shortness of breath. It includes asthma, chronic obstructive pulmonary disease (COPD), pneumonia, bronchitis, and lung infections. The rise in respiratory disorders is mainly due to rising air pollution, which increases the exposure to harmful pollutants that irritate the airways and worsen lung function. Budesonide inhalers manage respiratory disorders by delivering anti-inflammatory medication directly to the lungs, offering long-term control. Their compact design makes them easy to use and carry, reducing flare-ups and improving respiratory health. For instance, in June 2025, according to Public Health Wales, a UK-based National Health Service organization in Wales, the number of patients on asthma and chronic obstructive pulmonary disease registers in Wales is projected to increase over the next 10 years. Additioanlly, asthma is projected to increase to over 256,000 registered cases from 237,400 cases in 2023-24, and chronic obstructive pulmonary disease is projected to increase to over 84,000 cases from 75,600 cases in 2023-24. Therefore, the rising prevalence of respiratory disorders is driving the growth of the budesonide inhaler industry.

Key Players In The Global Budesonide Inhaler Market

Major companies operating in the budesonide inhaler market are AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Synmosa Biopharma Corporation, Chiesi Farmaceutici S.p.A., Aurobindo Pharma Limited, Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Orion Corporation, Nephron Pharmaceuticals Corporation, Curia Global Inc., Kindeva Drug Delivery L.P., Minakem SAS, Axplora Group GmbH, Cosmo Pharmaceuticals N.V., Manus Aktteva Biopharma LLP, Tovec Pharma Pvt. Ltd., Nutra Respiro Healthcare Pvt. Ltd.

Global Budesonide Inhaler Market Trends and Insights

Major companies operating in the budesonide inhaler market are focusing on developing innovative products, such as generic products, to improve affordability and ensure wider access to treatment for respiratory conditions. Generic inhalation products refer to non-branded versions of inhaled medications that deliver the same active ingredients, dosage, and therapeutic effects as their branded counterparts, typically at a lower cost. For instance, in July 2023, Viatris Inc., a US-based pharmaceutical company, in collaboration with Kindeva Drug Delivery L.P., a US-based pharmaceutical manufacturing company, launched Breyna (budesonide and formoterol fumarate dihydrate) inhalation aerosol, the first Food and Drug Administration (FDA), a US-based federal agency-approved generic version of Symbicort. This drug-device combination is designed to treat asthma and chronic obstructive pulmonary disease (COPD) and works by reducing inflammation in the airways with budesonide, while formoterol relaxes the muscles around the airways, offering patients a more affordable alternative.

What Are Latest Mergers And Acquisitions In The Budesonide Inhaler Market?

In January 2025, Molex, a US-based electronics company, acquired Vectura Group Ltd. for an undisclosed amount. With this acquisition, Molex aims to build an industry-leading capability in medical and inhalation drug delivery by combining Phillips Medisize's manufacturing expertise with Vectura's specialization in inhalation devices and formulation development, ultimately enhancing its ability to provide innovative therapies for respiratory conditions. Vectura Group is a UK-based pharmaceutical company that specializes in developing inhalation drug delivery systems, including those designed to deliver budesonide.

Regional Insights

North America was the largest region in the budesonide inhaler market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Budesonide Inhaler Market?

The budesonide inhaler market consists of sales of soft mist inhalers, nasal inhalers, budesonide repulse, oral inhalation capsules, and transdermal inhalation systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Budesonide Inhaler Market Report 2026?

The budesonide inhaler market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the budesonide inhaler industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.